3.74p -0.2 -4.1%
Last Trade - 9:52am
| Market Cap | ÂŁ11.5m |
| Enterprise Value | ÂŁ21.0m |
| Revenue | ÂŁ4.82m |
| Position in Universe | 1552nd / 1809 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.56 | 1.88 | 2.74 | 3.38 | 3.05 | 4.66 | +24.4% | ||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Proteome Sciences plc is a protein biomarker company specializing in proteomics and peptidomics services and applications, and mass spectrometry (MS) protein analysis. The Company is engaged in biomarker research and development in applied proteomics and workflows using its techniques to detect and characterize differentially expressed proteins in diseases for diagnostic, prognostic and therapeutic applications. It operates through the EU (the United Kingdom and Germany) and the United States geographic regions. Through the United Kingdom segment, it provides protein separation and MS capabilities for identification and analysis of post-translational modification of proteins in protein phosphorylation, image analysis and bioinformatics. Through the Germany segment, it provides protein profiling technologies, such as Tandem Mass Tags (TMT), which offers quantitation of proteins for the discovery of biomarkers. It has research agreements with various institutions in the United States.
| Last Annual | December 31st, 2019 |
| Last Interim | June 30th, 2020 |
| Incorporated | December 10, 1993 |
| Public Since | October 3, 1995 |
| No. of Shareholders: | n/a |
| No. of Employees: | 25 |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | FTSE Aim All Share , |
| Exchange | London Stock Exchange (AIM) |
| Shares in Issue | 295,182,056 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Hamilton House Mabledon Place, LONDON, WC1H 9BB, United Kingdom |
| Web | https://www.proteomics.com/ |
| Phone | +44 20 70432116 |
| Contact | () |
| Auditors | BDO LLP |
As of 9:52am, shares in Proteome Sciences are trading at 3.74p, giving the company a market capitalisation of ÂŁ11.5m. This share price information is delayed by 15 minutes.
Shares in Proteome Sciences are currently trading at 3.74p and the price has moved by 20% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Proteome Sciences price has moved by 13.95% over the past year.
Of the analysts with advisory recommendations for Proteome Sciences, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Proteome Sciences is Not available. You can view the full broker recommendation list by unlocking its StockReport.
Proteome Sciences is scheduled to issue upcoming financial results on the following dates:
Proteome Sciences does not currently pay a dividend.
Proteome Sciences does not currently pay a dividend.
Proteome Sciences does not currently pay a dividend.
To buy shares in Proteome Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Proteome Sciences are currently trading at 3.74p, giving the company a market capitalisation of ÂŁ11.5m.
Here are the trading details for Proteome Sciences:
Based on an overall assessment of its quality, value and momentum, Proteome Sciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Proteome Sciences are currently priced at 3.74p. At that level they are trading at 53.85% discount to the analyst consensus target price of 8.10.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Proteome Sciences. Over the past six months, the relative strength of its shares against the market has been -6.28%. At the current price of 3.74p, shares in Proteome Sciences are trading at 2.76% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Proteome Sciences PE ratio based on its reported earnings over the past 12 months is 0.186k. The shares are currently trading at 3.74p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Proteome Sciences's management team is headed by:
Here are the top five shareholders of Proteome Sciences based on the size of their shareholding:
